The present invention relates to transmucosal therapeutic systems for the transmucosal administration of an active agent comprising a mucoadhesive layer structure comprising a macrolide immunosuppressant as active agent, such transmucosal therapeutic systems for use in a method of treatment and/or prophylaxis, and processes of manufacture of such transmucosal therapeutic systems.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A device for removing a section from a web, in particular a film web, including at least one separating device for separating the section out of the web, and a guiding device. The guiding device movably guides the separating device in the direction of movement of the web. The invention also includes a system for processing a web and method for removing a section from a web.
B65H 35/00 - Delivering articles from cutting or line-perforating machinesArticle or web delivery apparatus incorporating cutting or line-perforating devices, e.g. adhesive tape dispensers
B26D 7/00 - Details of apparatus for cutting, cutting-out, stamping-out, punching, perforating, or severing by means other than cutting
B26D 7/18 - Means for removing cut-out material or waste
B26D 7/26 - Means for mounting or adjusting the cutting memberMeans for adjusting the stroke of the cutting member
3.
MEDICAL PATCH COMPRISING CAPSAICIN OR A CAPSAICIN ANALOG
The present invention relates to a medical patch for the administration of capsaicin or a capsaicin analog comprising an active agent-containing self-adhesive layer structure comprising capsaicin or a capsaicin analog, such a medical patch for use in a method of treatment as well as processes of manufacture of such a medical patch.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
4.
Microneedle Device and Method for Detecting At Least One Force Acting on a Microneedle Array
The invention relates to a microneedle device, in particular a manually applied microneedle device. The microneedle device has a microneedle array and a sensor device connected to the microneedle array. The sensor device is designed for detecting at least one force acting on the microneedle array. The invention also relates to a method for detecting at least one force acting on a microneedle array by means of a sensor device connected to the microneedle array. The invention further relates to a method for applying a microneedle array.
The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of cytisine comprising a self-adhesive layer structure containing a therapeutically effective amount of cytisine, such cytisine TTS for use in a method of treatment as well as processes for manufacturing such cytisine TTS.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
The present invention relates to an oral thin film comprising a matrix layer, wherein the matrix layer comprises lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer, and at least one polyvinyl alcohol with a mean molecular weight of 20,000 to 250,000 g/mol, a method for producing same, and the use of such an oral thin film as a medicament, especially in the treatment of schizophrenia, depression and/or bipolar disorders.
METHOD AND DEVICE FOR PRODUCING AN ADMINISTERING SYSTEM FOR A SWALLOWABLE OBJECT, ADMINISTERING SYSTEM AND DRINKING CUP SYSTEM FOR ADMINISTERING A SWALLOWABLE OBJECT
The invention relates to a method for producing an administering system (10) for a swallowable object (110), comprising the steps of: providing an object receptacle (14) for the swallowable object (110); providing a housing (12) for receiving the object receptacle (14); and fastening a holding-element loop (15) between the object receptacle (14) and the housing (12), the holding-element loop (15) comprising at least one holding element (16) to be fastened to the swallowable object (110). The invention also relates to an administering system (10), a drinking cup system (100), and a device for producing an administering system (10).
A61J 7/00 - Devices for administering medicines orally, e.g. spoonsPill counting devicesArrangements for time indication or reminder for taking medicine
9.
TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF TIZANIDINE
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
10.
TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID
The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention relates to a self-adhesive layer structure for use in a medical patch, having a pentagonal shape that comprises at least one pentagon, a medical patch and a sheet of medical patches comprising such self-adhesive layer structure(s) as well as such medical patches for use in a method of treatment and processes of manufacture of such medical patches.
The present invention relates to a microneedle array for use in the intradermal application of active substances, the array comprising a plurality of microneedles on a support which are formed of a formulation that contains a biodegradable polymer, an active substance and an antiseptic.
The present invention relates to a self-adhesive layer structure for use in a medical patch, having a hexagonal shape that comprises at least one hexagon, a medical patch and a sheet of medical patches comprising such self-adhesive layer structure(s) as well as such medical patches for use in a method of treatment and processes of manufacture of such medical patches.
The present invention relates to a medical patch for the administration of capsaicin comprising an active agent-containing layer structure comprising capsaicin, such as a medical patch for use in a method of treatment as well as processes of manufacture of such a medical patch.
The present invention relates to a medical patch for the administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising a backing layer, an active agent-containing layer and a skin contact layer, wherein the skin contact layer is an adhesive layer which is directly attached to the active agent-containing layer, and wherein the saturation concentration of the active agent in the skin contact layer is less than 0.1 % by weight, as well as to such a medical patch for use in a method of treatment and to a process of manufacture of such a medical patch.
The present invention relates to film delivery systems comprising a mucoadhesive layer, wherein the mucoadhesive layer comprises a film-forming agent and is provided with perforations.
The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of agomelatine comprising a self-adhesive layer structure containing a therapeutically effective amount of agomelatine, such agomelatine TTS for use in a method of treatment, a method of treatment comprising applying such agomelatine TTS, and processes of manufacture of such TTS.
RAPIDLY DISINTEGRATING ORAL THIN-FILMS/FOAMS HAVING A HIGH ACTIVE-INGREDIENT CONTENT BASED ON A MIXTURE OF POLYVINYL ALCOHOLS HAVING VARIOUS MOLECULAR WEIGHTS
The invention relates to an oral thin film comprising at least one matrix layer, wherein the at least one matrix layer comprises at least one polyvinyl alcohol having a low average molecular weight and at least one polyvinyl alcohol having a high average molecular weight and at least one pharmaceutical active substance. The invention also relates to the use of the oral thin film as a medicine.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
The present invention relates to a transdermal therapeutic system for the transdermal administration of huperzine A comprising a huperzine A-containing layer structure, said huperzine A-containing layer structure comprising A) a backing layer; and B) a huperzine A-containing layer.
The invention relates to an application device for microneedles (10), comprising a microneedle receiving portion (14), a reservoir receiving portion (16) for receiving a reservoir (108), and a contact barrier (17) for spacing apart a microneedle array (102) received in the microneedle receiving portion (14) and a reservoir (108) received in the reservoir receiving portion (16). The invention also relates to a system (100) for microneedle application and to a method for producing a system (100) for microneedle application.
A method for manufacturing a microneedle element, including the following steps: providing a mold element for the microneedle elements to be manufactured, filling the mold element with a first formulation, curing the first formulation, and pressurizing the first formulation during curing. Furthermore, a microneedle element and a device for manufacturing a microneedle element.
B29C 39/02 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor for making articles of definite length, i.e. discrete articles
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
B29C 39/40 - Compensating volume change, e.g. retraction
A method for impregnating a film, including the following steps feeding the film to be impregnated, immersing the film into an impregnating agent, and partially separating the impregnating agent from the film in order to achieve a predefined loading of the film with impregnating agent. Furthermore, a device for impregnating a film by means of an immersion basin filled with impregnating agent, a film guiding, and a separating device for separating the impregnating agent from the film in order to achieve a predefined loading of the film with impregnating agent. Furthermore, a method for manufacturing a transdermal therapeutic system.
B05C 3/12 - Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material the work being immersed in the liquid or other fluent material for treating work of indefinite length
Disclosed is a transdermal therapeutic system comprising an active agent impermeable backing layer, at least one adhesive layer comprising at least 70% by weight of at least one polysiloxane polymer, at least one tetrahydrocannabinol (THC) and at least one solubilizer, and optionally a protective layer for removal before use, a method for its preparation and its use as a medicament.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
24.
TRANSMUCOSAL THERAPEUTIC SYSTEM CONTAINING AGOMELATINE
The present invention relates to transmucosal therapeutic systems for the transmucosal administration of agomelatine comprising a mucoadhesive layer structure comprising a therapeutically effective amount of agomelatine, such agomelatine transmucosal therapeutic systems for use in a method of treatment, a method of treatment comprising applying such agomelatine transmucosal therapeutic systems, and processes of manufacture of such transmucosal therapeutic systems.
The present invention relates to oromucosal delivery systems for the transmucosal administration of an active agent comprising an active agent-containing layer comprising remimazolam, such remimazolam oromucosal delivery systems for producing sedation, a method of producing sedation comprising applying such remimazolam oromucosal delivery systems, and processes of manufacture of such remimazolam oromucosal delivery systems.
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
The present invention relates to a permeation cell, having a hollow body with at least two openings, characterized in that each of the at least two openings is closed by at least one semipermeable membrane. The invention also relates to a device for measuring permeation, to a method for measuring permeation and to the use of such a permeation cell for determining permeation.
A method for manufacturing an adherent film composite, including the following steps: (i) providing a laminate, the laminate including a first film, a second film, and an adherent formulation arranged between the first film and the second film; (ii) feeding the laminate in a feeding direction; (iii) and separating the first film with the formulation arranged thereon from the second film. The films are separated by the first film being fed out obliquely to the feeding direction from the second film, wherein the second film is passed on in the feeding direction. The first film rotates about its longitudinal axis when feeding out the first film. Furthermore, a device for manufacturing an adherent film composite.
The present invention relates to an oral thin film, comprising at least one layer which contains at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane, and to the use of such an oral thin film as a medicament.
The present invention relates to a multi-layer oral thin film comprising a matrix layer, which contains at least one polymer and at least one pharmaceutically active agent, and at least one backing layer, wherein the at least one backing layer comprises at least one polyethylene glycol, to a method for production of the oral thin film, and to the use of such an oral thin film as a medicament.
The present invention relates to a method for producing a water-erodible, water-soluble or water-dispersible active-ingredient-administering form, in which, firstly, a film suitable as an oral film-administering form is produced which contains the active ingredient and in which a surface of the film is activated in a subsequent step in order to generate a tacky surface, followed by rolling up the activated film to form a rolled-up laminate. The present invention also relates to rolled-up laminates produced according to this method. Corresponding laminates are very stable, such that they can be dispensed and cut, and are suitable on account of their area density, which is very high by comparison with conventional OTF products, for administering active ingredients which have to be given in larger amounts.
The present invention relates to an oral thin film comprising at least one matrix polymer and at least one active pharmaceutical ingredient, wherein the at least one active pharmaceutical ingredient is an acid or a base, characterised in that the at least one active pharmaceutical ingredient is present in the form of a mixture which comprises the at least one active pharmaceutical ingredient both in the form of the free acid or base and in the form of a pharmaceutically acceptable salt, a method for producing said oral thin film, and the use of such an oral thin film as a medicament.
The invention relates to a method and device for testing the adhesion of an adhesive, planar body on a planar substrate, wherein the planar body is applied adhesively on the substrate, the substrate is moistened, and a mechanical force is exerted on the substrate by means of an element in the form of a dumbbell-shaped magnetic stirring rod acting on the side of the substrate facing away from the adhesively applied body, wherein the substrate is repeatedly reversibly deformed at least in parts of the adhesive region of the planar body by means of the exertion of force, and, after a period of time, exertion of the mechanical force is ended, and the remaining adhesion of the planar body is assessed in qualitative and/or quantitative terms. A testing device is likewise disclosed, in which a force is exerted on the planar substrate by means of a movable element in the form of a dumbbell-shaped magnetic stirring rod acting on the side of the planar substrate facing away from the applied adhesive planar body and rotating below the substrate, deforming same.
Described is a test device for microneedle systems having a microneedle receptacle for receiving a microneedle system to be tested, an application device, and a movement device including a punch for the application in motion of the microneedle system to be tested in the application device. A test system with a test device of this kind is also described. Lastly, described is a method for testing a microneedle application.
The present disclosure relates to a multi-layer oral thin film comprising a first and a second matrix layer, which each contain at least one polymer, and a separation layer located between the first and the second matrix layer, wherein the separation layer comprises at least one polyethylene glycol, to a method for production of the oral thin film, and to the use thereof as a medicament.
provided is a method for manufacturing a mold element for the production of microarrays, including the following steps: (i) providing a planar base element having a first surface and a second surface opposite the first surface, (ii) providing a planar auxiliary element on the second surface, (iii) penetrating the base element from the first surface in order to form mold openings, and (iv) reversibly or non-reversibly entering the auxiliary element when penetrating the base element. Moreover, a mold element for the production of microarrays, including a planar base element having a first surface a second surface opposite the first surface, a planar auxiliary element arranged on the second surface, and several mold openings extending from the surface of the base element through the second surface of the base element.
The present invention relates to a method for producing a multi-layer oral thin film comprising the steps of a) providing a solution, an emulsion, a foam or a suspension comprising at least one first polymer, b) processing the solution, the emulsion, the foam or the suspension from step a) in order to obtain a polymer film, c) applying a powder comprising at least one second substance, which preferably differs from the first polymer, to the polymer film, and d) forming a composite between the polymer film and the powder applied in step c), to a multi-layer oral thin film obtainable by this method, and to the use of a multi-layer oral thin film obtainable by this method as a medicament.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention relates to an oral thin film comprising a polymer matrix in the form of a solidified foam having voids, wherein the polymer matrix contains at least one active pharmaceutical ingredient, at least one first polymer which comprises a water-soluble polymer and at least one second polymer which comprises a mucoadhesive polymer having a number-average molecular weight of equal to or greater than 100,000 g/mol, a method for producing the oral thin film, and the use of such an oral thin film as a medicament.
The present invention relates to a multi-layer thin film comprising at least two layers arranged one on top of the other which each comprise at least one polymer, these at least two layers being connected to one another by at least one stitched seam using at least one thread, and to a method for producing such a thin film and to the use thereof as a medicament.
The invention relates to a method for producing microstructures, the method including providing a planar mold element, which includes at least one mold opening for the microstructure to be produced, wherein the at least one mold opening has a first opening and a second opening; providing a first formulation at the second opening; generating a negative pressure in the mold opening; and taking up the first formulation through the second opening into the mold opening on account of the negative pressure in the mold opening. The invention further relates to a system for producing microstructures.
An active ingredient means for delivering an active ingredient, in particular a pharmaceutical active ingredient, includes an active ingredient means and an electronic means cooperating therewith. The active ingredient means includes an active ingredient reservoir fluidically connected to a delivery means. The electronic means, which is manufactured in particular as a separate component, includes a control means and a pumping means electrically connected thereto. The pumping means is used to convey the active ingredient from the active ingredient reservoir to the delivery means.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nicotine patches for use as aids to stop smoking; Transdermal patches featuring nicotine for the purpose of smoking cessation with a heated layer for the administration of nicotine for the purpose of smoking cessation
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nicotine patches for use as aids to stop smoking; Transdermal patches featuring nicotine for the purpose of smoking cessation with a heated layer for the administration of nicotine for the purpose of smoking cessation
The present invention relates to a kit comprising at least one microneedle system and at least one dosage form for transmucosally administering at least one pharmaceutically active ingredient, wherein the at least one dosage form for transmucosal administration comprises at least one pharmaceutically active ingredient, preferably an oral thin film, to this kit for use in the treatment of a patient, to the use of a microneedle system for reducing the permeation barrier of a mucosa for at least one pharmaceutically active ingredient, and to a method for treating a patient, wherein a microneedle system is firstly applied to a point of a mucosa of a patient and is removed again, and then an oral thin film comprising at least one matrix polymer and at least one pharmaceutically active ingredient is applied to the point of the mucosa where the microneedle system was applied and removed again, or wherein the microneedle system is applied to the mucosa simultaneously with a dosage form for transmucosally administering at least one pharmaceutically active ingredient. The present invention also relates to a biodegradable microneedle system comprising at least one pharmaceutically active ingredient and at least one biodegradable polymer.
A sensor device for detecting properties of a skin area, including at least one sensor unit; and a support device connected to the sensor unit. The support device can be connected to the skin area to be detected; the sensor unit includes a transmitter for outputting an electrical and/or magnetic signal to the skin area to be detected, and a receiver for measuring a signal originating from the skin area, which signal results from the signal output by the transmitter. The invention also relates to a use of such a sensor device. In addition, the invention relates to a method for detecting the properties of a skin area.
The present invention relates to aransdermal therapeutic system for the transdermal administration of a systemically active agent having a self-adhesive layer structure. The transdermal therapeutic system includes (A) a backing layer, and (B) a dried biphasic layer. The dried biphasic layer has (a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and (b) an inner phase having a composition that includes at least one active agent. The inner phase forms dispersed deposits in the outer phase, with the dried biphasic layer including (c) from 0.1% to 3.5% of an interface mediator other than silicone oil, with the interface mediator having with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Oral thin film comprising one or more layer(s), wherein at least one layer contains adrenaline or a pharmaceutically acceptable salt thereof and at least one polymer, characterized in that the adrenaline is substantially undissolved in the at least one polymer. Method for preparing said oral thin film, comprising the steps: a) Preparing a solution comprising said at least one polymer and a solvent in which adrenaline or the pharmaceutically acceptable salt thereof is substantially insoluble, (b) addition of adrenaline, (c) spreading and drying the suspension obtained in step (b), in order to obtain a single-layer oral thin film, and Said oral thin film for use as a medicament, for use as a medicament in the treatment of allergic reactions.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Oral thin film comprising adrenaline or a pharmaceutically acceptable salt thereof and at least one polymer, characterized in that the water activity of the oral thin film is less than 0.6. Method for preparing said oral thin film, comprising the steps of a) preparing a solution, dispersion or melt comprising adrenaline or a pharmaceutically acceptable salt thereof and at least one polymer and b) spreading the solution, dispersion or melt from step a) or the optionally foamed solution, dispersion or melt from step al) in order to obtain an oral thin film, and (c) drying the oral thin film obtained in step (b) in order to obtain an oral thin film having a water activity of less than 0.6. Said oral thin film for use as a medicament, particularly for use as a medicament in the treatment of allergic reactions.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 31/417 - Imidazole-alkylamines, e.g. histamine, phentolamine
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Nicotine patches for use as aids to stop smoking; transdermal patches, especially, plasters with a heated layer for the administration of nicotine.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Nicotine patches for use as aids to stop smoking; transdermal patches, especially, plasters with a heated layer for the administration of nicotine.
An intradermal active ingredient delivery system includes an extraction device, which in particular has a several hollow needles, for extracting interstitial liquid. A conveying device is fluidically connected to the extraction device. The conveying device is also fluidically connected to an active ingredient reservoir. The conveying device is fluidically connected to a delivery device for delivering an interstitial liquid comprising active ingredient. The delivery device preferably has hollow needles to be able to delivery the liquid mixture intradermally.
A temperature control system for a diffusion cell. The temperature control system includes a cell head and a temperature control device connected to the cell head. Moreover, a diffusion cell having such a temperature control system. Furthermore a diffusion cell system having such a temperature control system or such a diffusion cell. Finally, a method for controlling the temperature of a cell head of a diffusion cell, including introducing the temperature control fluid into the cell head.
G01N 1/44 - Sample treatment involving radiation, e.g. heat
G01K 5/48 - Measuring temperature based on the expansion or contraction of a material the material being a solid
F28D 1/06 - Heat-exchange apparatus having stationary conduit assemblies for one heat-exchange medium only, the media being in contact with different sides of the conduit wall, in which the other heat-exchange medium is a large body of fluid, e.g. domestic or motor car radiators with the heat-exchange conduits forming part of, or being attached to, the tank containing the body of fluid
G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
G05D 23/19 - Control of temperature characterised by the use of electric means
G05D 23/27 - Control of temperature characterised by the use of electric means with sensing element responsive to radiation
Described is an oral thin film comprising at least one matrix layer, wherein the at least one matrix layer comprises at least one pharmaceutically active agent, at least one polyvinyl alcohol and at least one polyvinyl alcohol-polyethylene glycol graft copolymer, a method for producing same, and use thereof as a medicament.
The invention relates to a transdermal therapeutic system, comprising a reservoir, which has a wall and an interior for receiving at least one pharmaceutically active ingredient in liquid form or for receiving a solution or suspension that comprises at least one pharmaceutically active ingredient, wherein at least one point on the wall of the reservoir is permeable to the at least one pharmaceutically active ingredient and wherein the reservoir has at least one inlet and at least one outlet for the at least one pharmaceutically active ingredient in liquid form or for the solution or suspension that comprises at least one pharmaceutically active ingredient. The invention also relates to a fixing system for fastening the reservoir on the skin of a patient, the transdermal therapeutic system for use in the field of medicine, the transdermal therapeutic system for use in the treatment of a patient, and a method for treating a patient.
The present invention relates to a process for the preparation of asenapine in the form of its free base, a process for the preparation of an active ingredient-containing layer for use in a transdermal therapeutic system, asenapine in the form of its free base, obtainable by said process for the preparation of asenapine in the form of its free base, an active ingredient-containing layer for use in a transdermal therapeutic system, obtainable by said process for the preparation of an active ingredient-containing layer and a transdermal therapeutic system containing such an active ingredient-containing layer.
The invention relates to systems formed from closed liquid-tight packaging and a preferably dimensionally stable aqueous composition which is sealed therein and which, upon activation, releases a liquid phase essentially composed of water in a time-delayed manner. The invention further relates to methods for manufacturing such systems and the use thereof during the production of self-decomposing transdermal therapeutic systems (TTS).
The invention relates to a method for producing a mold element for producing micro-arrays. First, a planar base element, in particular in the form of a film, is provided. Recesses are made in, in particular embossed into, an upper face of the element. The recesses are opened on a lower face of the base element in particular by using laser radiation. The invention also relates in particular to a mold element produced by means of this method, which mold element has recesses like the base element. Each of the recesses has openings in the lower face of the base element.
A mold element, in particular a casting mold for manufacturing microstructures, in particular microneedle arrays, includes a base body. On an upper side of the base body, several depressions for receiving material for manufacturing the microstructure are provided. In order to improve the quality of the microstructure to be manufactured, in particular during a drying process, channels are provided on the upper side of the base body, each of which is connected to at least one of the depressions.
The present invention relates to a microneedle system (MNS) for the intradermal delivery of interferon, wherein polyvinylpyrrolidone is the major constituent of a completely soluble formulation.
Disclosed is an oral thin film comprising a polymer matrix, which comprises an active pharmaceutical ingredient, a first polymer and a second polymer, wherein the first polymer is different from the second polymer and wherein the active pharmaceutical ingredient and the second polymer are a combination of a cationic active pharmaceutical ingredient and an anionic polymer, or a combination of an anionic active pharmaceutical ingredient and a cationic polymer, a method for its production and the medical use of that oral thin film.
The present invention relates to oromucosal therapeutic systems comprising a backing layer, an adhesive layer, and an active agent-containing layer, such oromucosal therapeutic systems for use in a method of treatment and/or prophylaxis, processes of manufacture of such oromucosal therapeutic systems as well as adhesive layers and bi-layer laminates for such oromucosal therapeutic systems.
The present invention relates to transmucosal therapeutic systems for the transmucosal administration of an active agent comprising a mucoadhesive layer structure comprising a macrolide immunosuppressant as active agent, such transmucosal therapeutic systems for use in a method of treatment and/or prophylaxis, and processes of manufacture of such transmucosal therapeutic systems.
The present invention concerns a transdermal therapeutic system, comprising a backing layer, which is not permeable N for the active ingredient, and at least one matrix layer on one side of the backing layer, wherein the matrix layer contains at least one pressure sensitive adhesive and ketamine or a pharmaceutically acceptable salt or solvate thereof, wherein the at least one pressure sensitive adhesive comprises a silicone pressure sensitive adhesive, as well as its use as medicament, in particular for the treatment of depression and pain.
The present invention relates to transmucosal therapeutic systems for the transmucosal administration of an active agent comprising a mucoadhesive layer structure comprising a macrolide immunosuppressant as active agent, such transmucosal therapeutic systems for use in a method of treatment and/or prophylaxis, and processes of manufacture of such transmucosal therapeutic systems.
The present invention relates to oromucosal therapeutic systems comprising a backing layer, an adhesive layer, and an active agent-containing layer, such oromucosal therapeutic systems for use in a method of treatment and/or prophylaxis, processes of manufacture of such oromucosal therapeutic systems as well as adhesive layers and bi-layer laminates for such oromucosal therapeutic systems.
A metering device for metering therapeutic fluids onto a support element including a container for providing the therapeutic fluid. A fluid dispensing device, in particular including pumps, is connected to the container. A dispensing head for dispensing the therapeutic fluids to the support element is connected to the fluid dispensing device. A movement device for moving the metering head during the delivery of the therapeutic fluid is provided for equalizing the application of the therapeutic fluid to the support element. The disclosure also relates to a corresponding method.
B05B 13/04 - Means for supporting workArrangement or mounting of spray headsAdaptation or arrangement of means for feeding work the spray heads being moved during operation
B05C 5/02 - Apparatus in which liquid or other fluent material is projected, poured or allowed to flow on to the surface of the work from an outlet device in contact, or almost in contact, with the work
The present invention relates to transdermal therapeutic systems for the transdermal administration of rotigotine containing a therapeutically effective amount of rotigotine base in a self-adhesive layer structure that includes a backing layer and a rotigotine-containing biphasic layer. The biphasic layer has an outer phase formed from a polymer or a polymer mixture along with an inner phase that includes rotigotine base and a polymer mixture including polyvinylpyrrolidone having a K-Value of at least 80 and at least one further hydrophilic polymer selected from the polymer groups: copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, copolymers of vinylpyrrolidone and vinylacetate, copolymers of ethylene and vinylacetate, polyethylene glycols, polypropylene glycols, acrylic polymers, and modified celluloses. The inner phase forms dispersed deposits in the outer phase. The inventive transdermal therapeutic systems optionally include a skin contact layer.
DDP Specialty Electronic Materials US 9, LLC (USA)
Inventor
Emgenbroich, Marco
Prinz, Eva-Marie
Klein, Elke
Kluth, Heike
Thomas, Xavier
Nartker, Linda Sue
Abstract
The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one silicone polymer.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61F 13/15 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the bodySupporting or fastening means thereforTampon applicators
79.
Device and method for dispensing active ingredient-containing or active ingredient-carrying strips
A device for dispensing active ingredient-containing or active ingredient-carrying strips, including a housing in which a coil chamber for receiving an active ingredient-containing or active ingredient-carrying band is arranged, in which a gear transmission with a driven roller for conveying the band is mounted, and in which a separating device for separating the strips from the band is arranged. A method for dispensing active ingredient-containing or active ingredient carrying strips using such a device is also disclosed. An active ingredient-containing or active ingredient-carrying band is arranged between the driven roller and the pressure roller. A shift clutch transmission having a manually actuatable trigger element is arranged upstream of the gear transmission. The driven roller can be driven in incremental strips by the shift clutch transmission. A device and method is disclosed for dispensing active ingredient-containing or active ingredient-carrying strips with a largely equal dosage are developed.
A61J 7/00 - Devices for administering medicines orally, e.g. spoonsPill counting devicesArrangements for time indication or reminder for taking medicine
B65D 83/08 - Containers or packages with special means for dispensing contents for dispensing thin flat articles in succession
B65H 35/00 - Delivering articles from cutting or line-perforating machinesArticle or web delivery apparatus incorporating cutting or line-perforating devices, e.g. adhesive tape dispensers
80.
METHOD FOR PRODUCING AN, IN PARTICULAR ORAL, ACTIVE SUBSTANCE LAMINATE, AND ACTIVE SUBSTANCE LAMINATE, IN PARTICULAR ORAL ACTIVE SUBSTANCE LAMINATE
The invention relates to a method for producing an active substance laminate, especially an oral active substance laminate (100), having at least one active-substance-containing layer (31), which is arranged on a substrate (20), wherein the method comprises the following steps:
a) providing a substrate (20) having an upper side (21) and an underside (22);
b) applying an active-substance-containing mass (24) in a gap (25) formed by a first rotating roller (26) and a second rotating roller (27);
c) transporting the substrate (20) to the second roller (27) by means of a third rotating roller (28) in such a way that the active-substance-containing mass (24) is applied to the upper side (21) of the substrate (20) by the second roller (27) in the form of an active-substance-containing layer (31);
d) transporting an intermediate laminate (30), formed by the substrate (20) and the active-substance-containing layer (31), to a drying device (40); and
e) drying the intermediate laminate (30), especially the active-substance-containing layer (31).
The present invention relates to a process for producing an oral thin film comprising microparticles, comprising the steps of:
a) producing a solution comprising a hydrophobic polymer, a hydrophobic pharmaceutically active ingredient and hydrophobic solvent,
b1) providing a hydrophilic polymer and providing a hydrophilic solvent immiscible with the solvent from a), or
b2) providing a solution comprising a hydrophilic polymer and a hydrophilic solvent immiscible with the solvent from a),
c1) mixing the solution from a) with the hydrophilic polymer from b1) followed by the addition of the hydrophilic solvent from b1) immiscible with the solvent from a) to obtain an emulsion, or
c2) mixing the solution from a) and the solution from b2) to obtain an emulsion, and
d) spreading and drying the emulsion from c1) or c2) to obtain an oral thin film comprising microparticles.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The invention relates to an oral thin film, comprising a matrix layer containing at least one polymer, wherein a microneedle system is applied to at least one surface of the oral thin film, to a method for producing such an oral thin film, to a composite, comprising such a thin film, and to an application aid, which comprises at least one polymer, for the oral thin film, wherein the oral thin film and the application aid are firmly connected to each other, to a method for producing the oral thin film, to a method for producing the composite, and to the oral thin film and to the composite for use as medicinal products.
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
The invention relates to a composite, comprising a first oral thin film and an application aid for the oral thin film, the oral thin film and the application aid being firmly connected to one another, to a method for the production thereof and to the composite for use as a medicament.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
The invention relates to an oral thin film, comprising a matrix layer containing at least one polymer, wherein a microneedle system is applied to at least one surface of the oral thin film, to a method for producing such an oral thin film, to a composite, comprising such a thin film, and to an application aid, which comprises at least one polymer, for the oral thin film, wherein the oral thin film and the application aid are firmly connected to each other, to a method for producing the oral thin film, to a method for producing the composite, and to the oral thin film and to the composite for use as medicinal products.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
The invention relates to a composite, comprising a first oral thin film and an application aid for the oral thin film, the oral thin film and the application aid being firmly connected to one another, to a method for the production thereof and to the composite for use as a medicament.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A device for producing a patch which includes a plurality of microstructures has at least one die. The die is used to produce a microstructure and has a plurality of depressions for this purpose. Additionally, a support layer, which is provided with an adhesive layer, is provided. In a preferred embodiment, it is possible to move the microstructure formed in the die in the direction of the support layer using a lifting device such that said microstructure adheres to the face of the support layer, which is provided with the adhesive layer. For example, by carrying out a corresponding method multiple times, multiple microstructures can be provided on the support layer adjacently to one another. Optionally, multiple dies can also be provided so that multiple microstructures can be simultaneously arranged on the support layer.
An apparatus for producing microarrays includes a die. A plurality of cavities is formed in the die. A cover element is additionally provided in order to cover regions between the cavities. In this manner it is possible to remove an active agent-containing liquid from the regions formed between the cavities when metering said liquid. This is achieved in that the cover element is removed again. An active agent-free liquid can then be metered, with which a remaining portion of the cavities are filled, and a support layer is formed on the upper surface of the die.
The present invention relates to a transdermal therapeutic system for administering diclofenac, comprising a backing layer and a matrix layer, the matrix layer containing diclofenac, at least one occlusive adhesive component and at least one solvent, characterized in that the at least one solvent comprises dimethylpropyleneurea. The invention also relates to its use as a medicament.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
The invention relates to a transdermal therapeutic system comprising a backing layer, an occlusive layer and at least one pharmaceutically active ingredient, the occlusive layer including at least one occlusive adhesive component on the basis of at least one polyisobutylene and at least one styrene block copolymer. The invention also relates to a system of this type for use as a medical product.
The present invention relates to iontophoretic compositions comprising a ketamine salt, a thickener in an amount to provide a viscosity of at least 500 mPas (at 20° C.), and water, and to their use for treating pain or depression. The present invention further relates to kits that comprise corresponding iontophoretic compositions and an iontophoresis device.
A carrier element for micro-needles for forming a micro-needle array has a plate-like base element. Mounting elements for respectively connecting to a micro-needle of the micro-needle array are provided on a front side of the base element. Connecting elements are also provided, in particular on the front side of the mounting elements. The connecting elements are formed in such a way that they have an undercut in the longitudinal direction such that the needles are reliably connected to the mounting elements.
The invention relates to an oral thin film, comprising a polymer matrix and ulipristal acetate as an active agent, wherein ulipristal acetate is dispersed in the polymer matrix and the polymer matrix is a matrix of water-soluble polymer selected from poly(ethylene oxide), poly(vinyl alcohol) or hydroxypropyl methylcellulose. The oral thin film is suitable as emergency contraceptive and can be administered in the oral cavity without water. It quickly disintegrates in the oral cavity wherein the active agent ulipristal acetate is mainly swallowed in undissolved form and absorbed into the gastrointestinal tract.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present invention relates to a transdermal therapeutic system for administering diclofenac, comprising a backing layer and a matrix layer, the matrix layer containing diclofenac, at least one occlusive adhesive component and at least one solvent, characterized in that the at least one solvent comprises dimethylpropyleneurea. The invention also relates to its use as a medicament.
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
The invention relates to a transdermal therapeutic system comprising a backing layer, an occlusive layer and at least one pharmaceutically active ingredient, the occlusive layer including at least one occlusive adhesive component on the basis of at least one polyisobutylene and at least one styrene block copolymer. The invention also relates to a system of this type for use as a medical product.
The invention relates to an oral thin film, comprising a polymer matrix and at least one water-insoluble, particulate active pharmaceutical ingredient dispersed in the polymer matrix, wherein the matrix polymer is poly(ethylene oxide) having a melting point of at least 55° C., the amount of poly(ethylene oxide) having a melting point of at least 55° C. is at least 40% by weight, based on the total weight of the oral thin film, and wherein the oral thin film is obtainable by a process comprising the steps of: a) preparing a suspension comprising the matrix polymer, the at least one water-insoluble, particulate active pharmaceutical ingredient and a solvent which s water or a mixture of water and one or more organic solvents, b) casting the suspension obtained on a support or in a mold, and c) drying the suspension at a temperature above the melting temperature of the poly(ethylene oxide).
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to a dosage form for transdermal administration of at least one active pharmaceutical ingredient with a logP≥3, comprising at least one penetration accelerator, wherein the at least one penetration accelerator comprises dimethylethylene urea, the use of such a dosage form as a medicament, and the use of dimethylethylene urea as penetration accelerator to increase the skin penetration of active pharmaceutical ingredients with a logP≥3.
A microneedle array has a plurality of microneedles, said microneedles being supported by a substrate. In order to improve the properties of the microneedle array, the substrate is in the form of a grid structure or comprises a grid structure.
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
B29C 33/42 - Moulds or coresDetails thereof or accessories therefor characterised by the shape of the moulding surface, e.g. ribs or grooves
100.
RAPIDLY DISINTEGRATING ORAL THIN-FILMS/FOAMS HAVING A HIGH ACTIVE-INGREDIENT CONTENT BASED ON A MIXTURE OF POLYVINYL ALCOHOLS HAVING VARIOUS MOLECULAR WEIGHTS
The invention relates to an oral thin-film comprising at least one matrix layer, wherein the at least one matrix layer comprises: at least one polyvinyl alcohol having a low average molecular weight; and at least one polyvinyl alcohol having a high average molecular weight; and at least one pharmaceutical active substance. The invention also relates to the use of the oral thin-film as a medicine.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
